Media Release
14 December 2020, Sensirion Holding AG, 8712 Stäfa, Switzerland

Sensirion: Forecast for full-year 2020 raised based on stronger than expected COVID-19 related business

Sensirion raises its forecast for the financial year 2020. As a result of continuing high demand for gas flow sensors in connection with the COVID-19 pandemic the sensor manufacturer expects now revenue for the full year of approximately CHF 254 million and an adjusted EBITDA margin in the mid-twenties percentage range.

One-time COVID-19 related demand for gas flow sensors stronger than expected
Based on the stronger than in August 2020 expected development of the medical ventilator-related business year to date, Sensirion Holding AG (Sensirion) raises its outlook for the full-year 2020 again. Revenue is now expected to approximately be CHF 254 million (previously CHF 210-230 million), of which approximately CHF 77 million stem from the ventilator projects (previous year CHF 7 million). The gross margin is projected to improve slightly through economies of scale, while the adjusted EBITDA margin is expected in the mid-twenties percentage range.

Despite increased sales in the second half of the year, Sensirion continues to expect demand from the one-time business in connection with the COVID-19 pandemic to normalize from the beginning of 2021. Regular business, not related to ventilator applications, developed as expected in August 2020. More detailed information will be provided when the annual report is published on 16 March 2021.

Sensirion to nominate Anja König for election to the Board of Directors
The Board of Directors of Sensirion will nominate Anja König for election to the previous six-member body at the upcoming Annual General Meeting 2021. As part of its long-term planning, the Board of Directors has decided to increase the number of members for one year. The nomination of Anja König will achieve this goal, while Heinrich Fischer will reach the extended age limit for members of the Board of Directors in 2022. The Board is convinced that Anja König is a very suitable candidate for recommendation to the Annual General Meeting. Because of her experience and broad knowledge of strategic investments and acquisitions, as well as her insight into the Swiss startup scene, she will provide Sensirion with significant support in its further development of strategic collaborations. A resume of Anja König can be found at the end of this press release.

Financial Calendar
16 March 2021 Financial year 2020 results and annual report
18 May 2021    Annual General Meeting 2021

Resume of Anja König, Swiss and German citizen, born in 1970
Anja König has been serving as Global Head of the Novartis Venture Fund since 2017, and between 2007 and 2017, she held the position of Managing Director. She currently serves on the boards of Forendo Pharma in Finland, Ribon Therapeutics in the USA and Arctos Medical in Switzerland. From 2006 until 2007, Anja König was Assistant to the Chairman and CEO of Novartis Inc. Prior to that, Anja König worked for McKinsey & Company as Associate Partner in New York between 2000 and 2006. Anja König received her PhD in Theoretical Physics from Cornell University, and her master's degree (Diploma) in Physics from the University of Munich.

Contact Investor Relations
Andrea Wüest
Director Investor Relations
Tel: +41 44 927 11 40
E-Mail: andrea.wueest@sensirion.com

About Sensirion Holding AG

Sensirion Holding AG (SIX Swiss Exchange: SENS), headquartered in Stäfa, Switzerland, is a leading manufacturer of digital microsensors and systems. The product range includes gas and liquid flow sensors, differential pressure sensors and environmental sensors for the measurement of humidity and temperature, volatile organic compounds (VOC), carbon dioxide (CO₂), and particulate matter (PM2.5). An international network with sales offices in China, Europe, Japan, South Korea, Taiwan, and the US supplies international customers with standard and custom sensor system solutions for a vast range of applications. Sensirion sensors can commonly be found in the automotive, medical, industrial, and consumer end markets. For further information, visit www.sensirion.com.

Disclaimer

Certain statements in this document are forward-looking statements, including, but not limited to, those using words such as "believe", "assume", "expect", and other similar expressions. Such forward-looking statements are based on assumptions and expectations and, by their nature, involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Such factors include, but are not limited to, future global economic conditions, changed market conditions, competition from other companies, effects and risks of new technologies, costs of compliance with applicable laws, regulations, and standards, diverse political, legal, economic and other conditions affecting markets in which Sensirion operates, and other factors beyond the control of Sensirion. In view of these uncertainties, you should not place undue reliance on forward-looking statements. Sensirion disclaims any intention or obligation to update any forward-looking statements, or to adapt them to future events or developments.

Certain financial data included in this document consists of "non-IFRS financial measures". These non-IFRS financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS. As a result, you are cautioned not to place undue reliance on any non-IFRS financial measures and ratios included herein.

This document is not an offer to sell, or a solicitation of offers to purchase, any securities.